Riarify (previously CHF 5993 Chiesi Farmaceutici S.p.A.) (beclometasone;formoterol)
- Region
- 🇪🇺 EU
- Active substance
- beclometasone;formoterol
- Company
- Chiesi Farmaceutici S.p.A.
- Status
- Withdrawn
- Therapeutic area
- Pulmonary Disease, Chronic Obstructive
- CHMP opinion
- Thu 22 Feb 2018
- EU approval
- Mon 23 Apr 2018
- Application
- EMEA/H/C/004836
- ATC
- R03AL09
- Official record
- www.ema.europa.eu
Indication
Maintenance treatment in adult patients with moderate to severe chronic obstructive pulmonary disease (COPD) who are not adequately treated by a combination of an inhaled corticosteroid and a long-acting beta2-agonist (for effects on symptoms control and prevention of exacerbations see section 5.1).
Regulatory milestones
No milestones recorded in the last year.
Same substance in other markets
- 🇪🇺 Trimbow Authorised · Chiesi Farmaceutici S.p.A.
- 🇪🇺 Trydonis Authorised · Chiesi Farmaceutici S.p.A.
Follow Riarify (previously CHF 5993 Chiesi Farmaceutici S.p.A.)
Get VigiEye Daily: approvals, opinions, safety actions and PDUFA dates every morning.
Information from official EMA, FDA, Federal Register and SEC records. Dates marked company-announced come from the company's own SEC filing; dates marked estimate are calculated, not official. Not investment or medical advice; always confirm on the source.